Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-PHL-C1 pediatric classical Hodgkin lymphoma study
NL-OMON41689Phase 3Active, not recruiting
- Sponsor
- SKion
- Start
- Jul 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of procarbazine, dacarbazine, vincristine, etoposide, prednisone and 2 more in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by SKion. Primary endpoints: 5-year event-free survival without radiotherapy after adequate response, Non-inferiority of dacarbazine substitution and 1 more. Started Jul 2011; status: active, not recruiting.
02
Drugs
procarbazinedacarbazinevincristineetoposideprednisone
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON41689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41689.